Table 3.

Last results of KEYNOTE 006, CheckMate 066 and CheckMate 067 trial.

	KEYNOTE 006 (53)	CheckMate 066 (54)	CheckMate 067 (55)
Treatment arm	Pembrolizumab	Nivolumab	Nivolumab + ipilimumab
Last update	5 years	5 years	5 years
mPFS	8.4	5.1	11.5
PFS	NR	28%	36%
mOS	32.7	37.3	NR (more than 60)
OS	38.7%	39%	52%
ORR	42%	42%	58%
trAEs G3–4	17%	15%	59%